Screener
Immunome IMNM Total Revenue
Total Revenue at other companies
Other financials
Where this comes from
Reported directly by Immunome in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Immunome’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:10 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219425
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Collaboration revenue | — | $2,926 |
| Operating expenses: | ||
| Research and development | 46,381 | 36,872 |
| General and administrative | 12,950 | 10,690 |
| Total operating expenses | 59,331 | 47,562 |
| Loss from operations | (59,331) | (44,636) |
| Interest income | 5,492 | 2,996 |
| Net loss | $(53,839) | $(41,640) |
Item 1. Financial Statements.
FAQ
- What is Immunome's total revenue?
- Immunome (IMNM) reported total revenue of $0 in Q1 2026.
- How has Immunome's total revenue changed year-over-year?
- Immunome's total revenue decreased by 100.0% year-over-year, from $2.93M to $0.
- What is the long-term trend for Immunome's total revenue?
- Over 2 years (2023 to 2025), Immunome's total revenue has grown at a -29.6% compound annual growth rate (CAGR), from $14.02M to $6.94M.
- What does total revenue mean?
- The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.
Ask your AI about Immunome's total revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude